JakobczukOlena
- Aurinia Pharmaceuticals (NASDAQ:AUPH) gained value in Thursday’s trading after the company announced a management restructuring.
- Peter Greenleaf, President and CEO of Aurinia (AUPH), remains a director.
- Kevin Tang, President of Tang Capital Management, LLC, Appointed Director.
- The Board has accepted the conditional resignations of three directors who did not receive majority support at the 2024 Annual General Meeting.
- The reorganized board consists of seven members: Jeffrey A. Bailey; Robert T. Foster, PhD, PharmD, PhD, DSc; Peter Greenleaf; David R. W. Jayne, MD, FRCP, FRCPE, FMedSci; Jill Leversage; Karen Smith, MD, PhD, MBA, LLM; and Kevin Tang.
- Source: Press release
